Semaglutide vs Tirzepatide
Two peptides people compare often—different categories, different label contexts. Read each profile before mixing routines or protocols.
Two peptides people compare often—different categories, different label contexts. Read each profile before mixing routines or protocols.
PubMed paper counts, ClinicalTrials.gov listings, and regulatory context—aggregated from public databases.
GLP-1 agonist
A GLP-1 receptor agonist peptide drug approved for type 2 diabetes and chronic weight management.
Semaglutide mimics glucagon-like peptide-1, slowing gastric emptying and increasing satiety. Weekly injection versions (Ozempic, Wegovy) produce significant weight loss in trials. It is a prescription drug—not a supple…
GLP-1 / GIP agonist
A dual GIP and GLP-1 receptor agonist with strong weight-loss and glycemic data in trials.
Tirzepatide activates both GLP-1 and GIP receptors—a newer mechanism than semaglutide alone. SURMOUNT trials showed ~20% body weight loss at higher doses. Prescription-only; side effects include nausea and rare pancrea…
Two peptides people compare often—different categories, different label contexts. Read each profile before mixing routines or protocols. Semaglutide is categorized as GLP-1 agonist; Tirzepatide as GLP-1 / GIP agonist. Semaglutide: A GLP-1 receptor agonist peptide drug approved for type 2 diabetes and chronic weight management. Tirzepatide: A dual GIP and GLP-1 receptor agonist with strong weight-loss and glycemic data in trials.
No. They are different molecules with distinct names on labels and in research databases. Always match the full INCI or drug name—not a nickname on the front of the package.
Prescription peptide drugs require a clinician and regulated pharmacy supply—they are not cosmetic INCI ingredients or bulk research powders sold like supplements.